Experienced in GTP Cyclohydrolase 1 Deficiency

Dr. Chatchada Karanes

Hematology | Oncology
1500 E Duarte Rd, 
Duarte, CA 
Clinical Trials:Currently Recruiting for 2 Trials
48 Years of Experience
Experienced in GTP Cyclohydrolase 1 Deficiency
1500 E Duarte Rd, 
Duarte, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Chatchada Karanes is a Hematologist and an Oncologist in Duarte, California. Dr. Karanes has been practicing medicine for over 48 years and is rated as an Experienced provider by MediFind in the treatment of GTP Cyclohydrolase 1 Deficiency. Her top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 38 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

1500 E Duarte Rd, Duarte, CA 91010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: November 24, 2025
Intervention Type: Drug
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Enrollment Status: Recruiting
Publish Date: April 19, 2024
Intervention Type: Biological
Study Phase: Phase 2
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Suspended
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-002 T Cells
Study Phase: Phase 1/Phase 2
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-001 T Cell Infusion
Study Phase: Phase 1/Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Biological
Study Drug: ProTmune Ex Vivo Programmed Mobilized Peripheral Cells
Study Phase: Phase 1/Phase 2
A Phase 1 Open-Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord
A Phase 1 Open-Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord
Enrollment Status: Completed
Publish Date: May 31, 2022
Intervention Type: Biological
Study Drugs: Unmanipulated Umbilical Cord Blood, AB-110
Study Phase: Phase 1
Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies
Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: July 06, 2021
Intervention Type: Drug, Radiation, Procedure, Biological
Study Drugs: Cyclophosphamide, Cyclosporine, Fludarabine, Mycophenolate Mofetil, Thiotepa
Study Phase: Phase 2
View 7 Less Clinical Trials

38 Total Publications

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm.
Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm.
Journal: Blood
Published: June 07, 2024
Similar Doctors
Advanced in GTP Cyclohydrolase 1 Deficiency
Dr. George Hajjar
Hematology | Oncology
Advanced in GTP Cyclohydrolase 1 Deficiency
Dr. George Hajjar
Hematology | Oncology

City Of Hope Medical Foundation

23823 Valencia Blvd, Ste 250, 
Santa Clarita, CA 
 (38.5 miles away)
661-799-1999
Languages Spoken:
English, Arabic, Spanish
See accepted insurances
Offers Telehealth

George Hajjar is a Hematologist and an Oncologist in Santa Clarita, California. Dr. Hajjar is rated as an Advanced provider by MediFind in the treatment of GTP Cyclohydrolase 1 Deficiency. His top areas of expertise are Pleuropulmonary Blastoma, Squamous Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

Advanced in GTP Cyclohydrolase 1 Deficiency
Dr. Roman L. Kleynberg
Hematology Oncology | Hematology | Oncology
Advanced in GTP Cyclohydrolase 1 Deficiency
Dr. Roman L. Kleynberg
Hematology Oncology | Hematology | Oncology

Advanced Hematology Oncology Medical Group Inc

6221 Wilshire Blvd, Suite 504, 
Los Angeles, CA 
 (22.8 miles away)
323-965-9995
Languages Spoken:
English
See accepted insurances

Roman Kleynberg is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Kleynberg is rated as a Distinguished provider by MediFind in the treatment of GTP Cyclohydrolase 1 Deficiency. His top areas of expertise are Leukocytosis, Thrombocytopenia, Blood Clots, Gastrostomy, and Colonoscopy.

Advanced in GTP Cyclohydrolase 1 Deficiency
Dr. Sarah M. Larson
Hematology Oncology | Hematology | Oncology
Advanced in GTP Cyclohydrolase 1 Deficiency
Dr. Sarah M. Larson
Hematology Oncology | Hematology | Oncology

The Regents Of The University Of California

2020 Santa Monica Blvd, Suite 210, 
Santa Monica, CA 
 (29.8 miles away)
310-458-2381
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sarah Larson is a Hematologist Oncology specialist and a Hematologist in Santa Monica, California. Dr. Larson is rated as a Distinguished provider by MediFind in the treatment of GTP Cyclohydrolase 1 Deficiency. Her top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Karanes's expertise for a condition
ConditionClose
View All 15 Advanced Conditions
View All 40 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile